BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management
June 13, 2018 08:00 ET
|
BioXcel Therapeutics, Inc.
Building strong clinical team to effectively support robust clinical programsDr. Burg to leverage his international experience to expand the Company’s clinical trials globally BRANFORD, Conn., June ...
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
June 07, 2018 08:00 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
June 05, 2018 08:00 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., June 05, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting
June 04, 2018 08:30 ET
|
BioXcel Therapeutics, Inc.
BXCL701 in Combination with NKTR-214 and anti-PD-1 Therapy Leads to Complete and Sustained Tumor Regression and Immune Memory in Pre-Clinical Syngeneic Models Results Support Further Development of...
BioXcel Therapeutics to Present at 2018 UBS Global Healthcare Conference
May 18, 2018 08:00 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., May 18, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting
May 17, 2018 08:00 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., May 17, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
May 14, 2018 16:01 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., May 14, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting
April 26, 2018 08:30 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., April 26, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics to Ring the NASDAQ Stock Market Opening Bell on April 20, 2018
April 19, 2018 08:30 ET
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., April 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...